Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1NET 1Endocrine 1

Conditions

Colorectal Neoplasms 49Rectal Neoplasms 32Pancreatic Neoplasms 28Colonic Neoplasms 24Stomach Neoplasms 19Neoplasm Metastasis 15Neoplasms 13Esophageal Neoplasms 10Breast Neoplasms 7Head and Neck Neoplasms 6Recurrence 5Lung Neoplasms 5Carcinoma, Non-Small-Cell Lung 5Adenocarcinoma Of Esophagus 5Lymphoma, Large B-Cell, Diffuse 4Carcinoma, Hepatocellular 4Ovarian Neoplasms 3Lymphoma, Extranodal NK-T-Cell 3Liver Neoplasms 3Gastrointestinal Neoplasms 3Gallbladder Neoplasms 3Fallopian Tube Neoplasms 3Cholangiocarcinoma 3Adenocarcinoma 3Unspecified Adult Solid Tumor, Protocol Specific 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Peritoneal Neoplasms 2Myelodysplastic Syndromes 2Melanoma 2Lymphoma, Non-Hodgkin 2

Interventions

Everolimus 2romidepsin 1pentetreotide 1Oxaliplatin 1Octreotide 1Leucovorin 1Fluorouracil 1Doxorubicin 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Gastrinoma × Oxaliplatin × Clear all
NCT00227617 2023-05-22

Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors

University of California, San Francisco

Phase 2/3 Terminated
36 enrolled 14 charts
EndocrineNETThoracic

Vipoma, Glucagonoma, Insulinoma, Adenoma, Islet Cell, Lung Neoplasms, Neoplasms, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡